CELU

The acquisition of Celularity's degenerative wound segment is described as a transformational step that evolves NEXGEL into a scalable, diversified medical technology business. Management attributes the deal's value to acquiring six established, commercial-stage regenerative biomaterial products with over a decade of clinical use and existing reimbursement pathways. The transaction is expected to triple annual revenue run rate to approximately $35 million and be immediately accretive to profitability upon closing. A key strategic driver is the acquisition of an experienced commercial team and a network of independent sales reps, providing the medical sales force NEXGEL previously lacked to sell its own devices like SilverSeal. The partnership with Sequence LifeScience provides not only capital but also backup manufacturing, product development expertise, and additional distribution channels. Management noted that while the market initially reacted negatively, they believe the acquisition of regenerative medicine assets represents a significant opportunity that will be immediately accretive to profitability. Management expects the company to be EBITDA profitable starting in the third quarter of 2024, driven by the integration of the new high-margin surgical products. Revenue modeling suggests a return to historical levels of $50 million within two years, supported by the re-engagement of sales representatives and the launch of new pipeline products. Based on the acquired business performing at the same level as the previous year, models suggest $4 million to $4.5 million in EBITDA on revenue of $22 million to $23 million. Future growth is dependent on 'Project SPARK,' a placental-based tendon wrap scheduled for 2026, which management believes has $40 million to $70 million in standalone revenue potential. The financial strategy includes using the shift to profitability to move to 'offense,' potentially utilizing stock buybacks if the share price does not reflect company value. The deal involved a complex '4-way trade' including $5.3 million cash at closing, a $5 million convertible note, and the assumption of $2.9 million in back commissions owed to sales reps. The convertible notes carry a 10% coupon and an 18-month maturity with a $0.60 conversion price; failure to reach profitability could make repayment difficult. NEXGEL will pay low single-digit royaltie...

LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to provide additional time for the Company to provide shareholders with greater detail regarding its previously announced proposed transaction with Celularity Inc. The Company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission today, March 31, 2026. Fourth Quarter and Full Year 2025 Financial Results Conference Call Details: Date: April 8, 2026 Time: 4:30 P.M. ET Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International) Webcast: Events and Presentations About NEXGEL, Inc. NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking st...

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery disease Celularity PDA-002 achieved durable wound healing with just two intramuscular doses As a qualified stem cell therapy under Florida statute (§ 458.3245), effective July 1, 2025 authorizing use in wound care, orthopedics, and pain management, PDA-002 may offer licensed Florida physicians an important new tool in treating DFU patients. FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the publication of its Phase 2 study titled “Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial,” in the International Wound Journal. Results of this study demonstrated safety and efficacy in a complex type of serious wounds in the setting of diabetes and peripheral vascular disease. Celularity’s Chairman and CEO, Robert J. Hariri, M.D., Ph.D., also commented on PDA-002 as a stem cell therapy which qualifies under a recently enacted Florida law expanding access in the state to stem cell therapies not yet approved by the U.S. Food and Drug Administration. Approximately two million individuals in the United States are affected each year by diabetic foot ulcers (DFU), nearly half of whom have coexisting peripheral artery disease (PAD). DFU complicated by PAD represents one of the most difficult and costly challenges in wound care. Currently, there are no U.S. Food and Drug Administration (FDA)-approved therapies specifically indicated for DFU with PAD. The estimated annual economic burden of treating DFU alone exceeds $9 billion in the United States. The presence of PAD significantly compromises lower-extremity perfusion, leading to chronic tissue ischemia, impaired angiogenesis, and delayed wound repair. PAD-associated DFUs are further characterized by persistent inflammation, altered immune response, and diminished responsiveness to standard wound care interventions. Despite five FDA-approved DFU therapies, none are currently approved for DFU complicated by PAD, underscoring the need for novel regenerative approaches that restore tissue perfusion and accelerate wound closure. The publis...

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan. Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1). FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The Quarterly Reports on Form 10-Q can be accessed on the SEC's website at www.sec.gov and in the investor relations section of the Company’s website at https://celularity.com/sec-filings. “I am pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025, as a result of which we have regained compliance with the Nasdaq Listing Rule 5250(c)(1). This is another important step for Celularity, as it comes on the heels of the recently announced retirement of all $32.0 million of the Company’s senior secured debt plus $9.6 million in associated unpaid interest, the Asset Purchase Agreement and a License Agreement with Celeniv Pte. Ltd., and an internal restructuring that includes establishing operating subsidiaries for each of its functional business units,” said Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and CEO. “The Company dealt with a set of challenges during the first half of 2025, including a significant secured debt overhang. As announced previously, we retired all senior secured debt and the associated general security interest on Company assets is now gone. Also in the first half of 2025, some since-resolved directional uncertainty around wound care product reimbursement policy added to the normal lag between commercial advanced biomaterial product sales and cash collections. Coming as it did on the heels of substantial growth in the second half of 2024 of our wound care related commercial product sales and Accounts Receivable, this factor contributed to working capital pressures during the first half of 2025. Today, however, we believe the Company is well positioned to access tradi...

Revenue: US$5.74m (down 53% from 2Q 2024). Net loss: US$24.5m (loss widened by 278% from 2Q 2024). US$1.02 loss per share (further deteriorated from US$0.30 loss in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Celularity shares are up 4.0% from a week ago. Be aware that Celularity is showing 3 warning signs in our investment analysis and 2 of those shouldn't be ignored... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced operating and financial results for the year ended December 31, 2024. “We built momentum through 2024 and ended the year with a strong finish, as reflected in higher net revenues from the sale of our commercial-stage advanced biomaterial products," said Dr. Robert Hariri, M.D., Ph.D., CEO and Chairman. “Sales growth was notably strong for our Biovance® product line, which we believe will continue to contribute to an improving revenue outlook for the next several quarters. We were also extremely pleased to receive recommendation letters from the U.S. Food and Drug Administration Tissue Reference Group regarding important additions to our portfolio of human placental-derived advanced biomaterial products, which serves as a testament to our commitment to innovate in the wound care sector along with our development of next-generation 510(k) products. At the same time, we continued to act opportunistically and explore opportunities in the rapidly evolving landscape of cellular and regenerative medicine. We believe Celularity will gain additional momentum in 2025 as we leverage our unique business model and world-class technical infrastructure and human capital.” Highlights of Full Year 2024 Operating and Financial Results Net Revenues Net revenues for the year ended December 31, 2024, was $54.2 million, an increase of $31.4 million, or 138.1%, compared to the prior year period. This growth was primarily due to a $22.2 million increase in product sales in wound care applications, which increased 168.7% over the prior year. Operating Expenses Total operating expenses for the year ended December 31, 2024, were $92.6 million, a decrease of $122.5 million, or 57.0%, compared to 2023. The decrease in operating expenses is attributable to the absence of goodwill and in-process research and development, or IPR&D, impairments in 2024. Loss from operations for the year ending December 31, 2024, was $38.4 million, a decrease of $153.9 million, or 80.1%, compared to the previous year, driven by higher revenue and lower operating expenses which improved ou...